Research presented at ASCO's annual meeting underscores the need for more cancer susceptibility studies in diverse populations, experts say.
First-line treatment with the anti-PD-1 drug Jemperli prompted a clinical complete response in 12 early-stage rectal carcinoma patients, who have been able to avoid further treatment so far.
Pooled analyses showed high PD-L1 expressers could do well with just immunotherapy, while most patients benefited more on chemo-immunotherapy regardless of KRAS status.
Along with germline sequencing results, the research team tracked recommendations by pediatric oncologists in response to structured email reports outlining the results.
Using transcriptome data from more than 38,600 tumor samples, investigators flagged expression patterns that may coincide with higher SARS-CoV-2 infections.
Within the KiCS study researchers found targetable mutations in more than half of the kids, but few actually received drugs based on those molecular markers.
Interim results from a study in the Netherlands suggest whole-genome sequencing can be done fast enough to uncover treatment targets in metastatic cancer patients.
Following variable Phase III outcomes, investigators are searching for more informative biomarkers than PD-L1 expression in advanced urothelial carcinoma cases.
Patients with discordant p16 and HPV markers fall into an intermediate risk group, research presented at the European cancer conference suggests.
Adult participants will have access to saliva-based testing from Invitae for the Screen Project, which aims to find clinically actionable BRCA1/2 mutations.